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AAI, 7-deoxyguanosin-N2-yl)aristolactam I; HPLC, high performance liquid 
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ABSTRACT 
Aristolochic acid I (AAI) is a natural plant alkaloid causing aristolochic acid nephropathy, 
Balkan endemic nephropathy and their associated urothelial malignancies. One of the most 
efficient enzymes reductively activating AAI to species forming AAI-DNA adducts is 
cytosolic NAD(P)H:quinone oxidoreductase 1. AAI is also either reductively activated or 
oxidatively detoxified to 8-hydroxyaristolochic acid (AAIa) by microsomal cytochrome P450 
(CYP) 1A1 and 1A2. Here, we investigated which of these two opposing CYP1A1/2-
catalyzed reactions prevails in AAI metabolism in vivo. The formation of AAI-DNA adducts 
was analyzed in liver, kidney and lung of rats treated with AAI, Sudan I, a potent inducer of 
CYP1A1/2, or AAI after pretreatment with Sudan I. Compared to rats treated with AAI alone, 
levels of AAI-DNA adducts determined by the 32P-postlabeling method were lower in liver, 
kidney and lung of rats treated with AAI after Sudan I. The induction of CYP1A1/2 by Sudan 
I increased AAI detoxification to its O-demethylated metabolite AAIa, thereby reducing the 
actual amount of AAI available for reductive activation. This subsequently resulted in lower 
AAI-DNA adduct levels in the rat in vivo. Our results demonstrate that CYP1A1/2-mediated 
oxidative detoxification of AAI is the predominant role of these enzymes in rats in vivo, 
thereby suppressing levels of AAI-DNA adducts. 
 
 
Key words: Aristolochic acid I; Cytochromes P450 1A1 and 1A2; Oxidative detoxification; 
Reductive activation; DNA adducts.  
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1. Introduction 
Aristolochic acid (AA) is a herbal drug prepared from plants of the Aristolochia genus 
containing nitrophenanthrene carboxylic acids, of which 8-methoxy-6-nitro-phenanthro-(3,4-
d)-1,3-dioxolo-5-carboxylic acid (aristolochic acid I, AAI) (Fig. 1) and 6-nitro-phenanthro-
(3,4-d)-1,3-dioxolo-5-carboxylic acid (AAII) are the predominant components  (Arlt et al., 
2002b). Over twenty years ago, AA was shown to be the cause of a unique renal disease 
formerly called Chinese herbs nephropathy, now referred to as aristolochic acid nephropathy 
(AAN) (for a review, see Arlt et al., 2002b; Schmeiser et al., 2009; Gökmen et al., 2013). 
AAN is a rapidly progressive renal fibrosis with a high risk for upper urothelial tract 
carcinoma (UUC) and, subsequently, bladder urothelial carcinoma (Vanherweghem et al., 
1993; Nortier et al., 2000; Arlt et al., 2002b; Yun et al., 2012; Gökmen et al., 2013). AA has 
been classified as a Group I carcinogen by IARC (IARC, 2012). Exposure to AA has also 
been found to be the cause of a similar type of renal disease, Balkan endemic nephropathy 
(BEN) and its associated occurrence of urothelial malignancy (Arlt et al., 2007; Grollman et 
al., 2007). This disease is endemic in certain rural areas of Balkan countries near the 
tributaries of the Danube river (Schmeiser et al., 2012).  
 Characteristic AA-DNA adducts in renal tissue of AAN and BEN patients are 
biomarkers of exposure to AA even long after AA exposure, the 7-(deoxyadenosin-N6-
yl)aristolactam I (dA-AAI) adduct being the most abundant adduct formed and the most 
persistent (Nortier et al., 2000; Arlt et al., 2002a, b; Schmeiser et al., 2012, 2014). This 
deoxyadenosine adduct causes characteristic A to T transversion mutations and such 
mutations were found in the TP53 tumour suppressor gene in tumors from AAN and BEN 
patients (Lord et al., 2004; Grollman et al., 2007) and in immortalized Hupki (human TP53 
knock-in) mouse fibroblasts (HUFs) exposed to AAI (Nedelko et al., 2009). This feature 
indicates a molecular mechanism of AA-mediated carcinogenesis (Arlt et al., 2007; Kucab et 
al., 2010). More recently, these A to T transversion mutations were also observed in loci of 
other genes by whole-genome and exome sequencing analyzing AA-associated UUC and 
AAI-treated HUFs (Poon et al., 2013; Hoang et al., 2013; Nik-Zainal et al., 2015).  
 Nitro-reduction of AAI, the compound that is considered as the major cause for AA-
mediated development of AAN and BEN, is required to exert its carcinogenic properties (i.e. 
UUC development) (Schmeiser et al., 1996, 2009; Arlt et al., 2002b; Stiborová et al., 2008a; 
Gökmen et al., 2013). Such nitro-reduction leads to the formation of N-hydroxylated 
aristolactam I which either converts to a reactive cyclic acylnitrenium ion generating DNA 
adducts or rearranges to 7-hydroxyaristolactam I (Schmeiser et al., 2009). The product of 
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AAI oxidation, 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa), is formed by O-
demethylation of the methoxy group (Fig. 1), and is a detoxification product of this 
carcinogen. AAIa is excreted either in its free form or conjugated (Chan et al., 2006; 
Shibutani et al., 2010; Arlt et al., 2011; Stiborová et al., 2012). 
 Various enzymes are involved in the metabolism of AAI. A variety of studies by us 
and others have shown that the cytosolic nitroreductase, NAD(P)H:quinone oxidoreductase 
(NQO1), is the most efficient enzyme activating AAI to DNA adducts (Stiborová et al., 
2002a, 2003, 2008a, b, 2011a, 2013b, 2014a, b, c; Martinek et al., 2011; Chen et al., 2011). In 
human and rodent hepatic microsomes AAI is also activated by cytochrome P450 (CYP) 1A2 
and, to a lesser extent, by CYP1A1 and NADPH:cytochrome P450 oxidoreductase (POR) 
(Stiborová et al., 2001; 2005a, b, 2008a, b, 2011b, 2012, 2013b, 2014a, b, c; Arlt et al., 2011, 
2015a; Levová et al., 2011, 2012; Jerabek et al., 2012) (Fig. 1). However, human and rodent 
CYP1A1 and 1A2 play a dual role in the metabolism of AAI. Under anaerobic conditions 
they reductively activate AAI, while under oxidative conditions they are the predominant 
enzymes catalyzing O-demethylation of AAI to AAIa (i.e. detoxication) (Stiborová et al., 
2001, 2005a, b, 2008a, b, 2011b, 2012, 2013b, 2014a, b, c; Sistkova et al., 2008; Rosenquist 
et al., 2010; Arlt et al., 2011; Levová et al., 2011). Beside CYP1A/2, rat and human CYPs of 
the 2C and 3A subfamilies also oxidize AAI (Sistkova et al., 2008; Rosenquist et al., 2010; 
Levová et al., 2011; Stiborová et al., 2012, 2015a, b) (Fig. 1). The CYP-mediated AAI 
oxidation leads to a decrease in AAI-induced renal injury (Xiao et al., 2008; Xue et al., 2008).  
The crucial role of CYP1A1 and 1A2 enzymes in AAI metabolism in vitro was 
unambiguously proven using several systems containing these enzymes [i.e. microsomal 
systems, inhibitors of these enzymes and correlation analyses, recombinant human and rat 
CYP1A1/2 heterologously expressed in microsomes of insect cells (SupersomesTM), purified 
enzymes reconstituted with POR and other components of the monooxygenase system] 
(Stiborová et al., 2001, 2005a, b, 2011b, 2012, 2013b, 2014a, b, c; Sistkova et al., 2008; Arlt 
et al., 2011; Levová et al., 2011). In addition, the importance of CYP1A1 and 1A2 in AAI 
metabolism has been demonstrated in vivo using Cyp1a1/2-knock-out (single and double 
knock-outs) and CYP1A-humanized mouse lines (Rosenquist et al., 2010; Arlt et al., 2011; 
Stiborová et al., 2012, 2014a, b, c). Based on current knowledge we proposed that AAI 
metabolism by CYP1A1/2 in vivo is determined by the binding affinity of AAI to these 
CYPs, and their enzymatic turnover as well as by the oxygen levels in the organs (Stiborová 
et al., 2012, 2013b, 2014a, b). Even though several studies considered CYP1A1/2 to be 
enzymes that detoxify AAI in vivo (Xiao et al., 2008; Rosenquist et al., 2010; Arlt et al., 
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2011; Stiborová et al., 2012, 2014a, b, c), the question which of their two opposing roles in 
AAI metabolism (AAI detoxification to AAIa versus activation of AAI to form AAI-DNA 
adducts) prevails in vivo remains to be answered.  
To elucidate the roles of CYP1A this study was performed. AAI was administered to 
Wistar rats pretreated with Sudan I (1-phenylazo-2-naphthol), a strong inducer of CYP1A1 
and CYP1A2 (Refat et al., 2008; Stiborová et al., 2013a), and AAI-DNA adduct levels in 
target and non-target organs were determined by 32P-postlabeling and compared to those in 
organs of rats treated with AAI only. The amounts of CYP1A1/2 enzymes expressed in rats at 
transcriptional and translational levels were analyzed by real-time polymerase chain reaction 
(RT-PCR) and Western blotting, and their activities determined with their marker substrates. 
The formation of AAIa, the detoxification metabolite of AAI, was analyzed using high 
performance liquid chromatography (HPLC).  
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2. Materials and methods 
2.1. Chemicals  
NADPH, AAI (sodium salt), Sudan I [1-(phenylazo)-2-hydroxynaphthalene], menadione 
(2-methyl-1,4-naphthoquinone), cytochrome c and calf thymus DNA were from Sigma 
Chemical Co (St Louis, MO, USA). 7-Methoxyresorufin was purchased from Fluka Chemie 
AG (Buchs, Switzerland). All these and other chemicals were reagent grade or better. 
Enzymes and chemicals for the 32P-postlabeling assay were from sources already described 
(Stiborová et al., 2005a).  
 
2.2. Animal experiments and sample preparation 
The study was conducted in accordance with the Regulations for the Care and Use of 
Laboratory Animals (311/1997, Ministry of Agriculture, Czech Republic), which is in 
compliance with the Declaration of Helsinki. Animals were purchased from AnLab (Prague, 
Czech Republic), acclimatized for 5 days and maintained at 22°C with a 12 h light/dark 
period. Standardized diet and water were provided ad libitum. One group of five weeks old 
male Wistar rats (125-150 g, n = 3/group) was treated i.p. with a single dose of AAI 
dissolved in 1% NaHCO3 (20 mg/kg body weight, bw), the second group with two doses of 
Sudan I dissolved in maize oil (i.p., always with 30 mg/kg bw) in two consecutive days, and 
the third group, where rats were treated i.p. with two doses of Sudan I (always with 30 mg/kg 
bw in two consecutive days) and with AAI (20 mg/kg bw) 24 hrs after the second dose of 
Sudan I-treatment. Three control rats received the same volume of both vehicles only. 
Animals were killed 1 day after the treatment by cervical dislocation. Livers, kidneys and 
lungs were removed, immediately after sacrifice, frozen in liquid nitrogen and stored at ‒80o 
C. DNA from livers, kidneys and lungs was isolated by extraction with phenol/chloroform 
(Schmeiser et al., 1996). Total RNA was isolated from another aliquot of frozen organs using 
Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the procedure supplied by the 
manufacturer. The quality of isolated RNA was verified by horizontal agarose gel 
electrophoresis, RNA quantity was assessed by UV-VIS spectrophotometry on a Carry 300 
spectrophotometer (Varian, Palo Alto, CA, USA). Microsomes and cytosols were isolated 
from the rat tissues by a procedure described previously (Stiborová et al., 2003, 2005a). 
Protein concentration in the microsomal and cytosolic fractions was measured using 
bicinchoninic acid protein assay (Wiechelman et al., 1988) with bovine serum albumin as a 
standard. Pooled microsomal and cytosolic samples (n = 3 rats/group) were used for analyses. 
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All microsomal and cytosolic samples were free of residual Sudan I, AAI or their metabolites 
as determined by HPLC (Stiborová et al., 1988, 2002b, 2005c; Levová et al., 2011). 
 
2.3. DNA adduct analysis by 32P-postlabeling  
The nuclease P1 enrichment version of 32P-postlabeling analysis, and thin-layer 
chromatography (TLC) on polyethylenimine-cellulose (PEI) plates were carried out and DNA 
adduct levels (RAL, relative adduct labeling) were calculated as described previously 
(Schmeiser et al., 1996, 2013). AAI-DNA adducts were identified using reference standards 
as described (Schmeiser et al., 1996).  
 
2.4. CYP1A and NQO1 mRNA content in rat livers, kidneys and lungs.  
RNA samples (1 μg) were reverse transcribed using 200 U of reverse transcriptase per 
sample with random hexamer primers utilizing RevertAidTM First Strand cDNA Synthesis Kit 
(MBI Fermentas, Vilnius, Lithuania) according to the manufacturer's instructions. The 
prepared cDNA was used for real-time (RT) polymerase chain reaction (PCR) performed in 
RotorGene 2000 (Corbett Research, Sydney, Australia) under the following cycling 
conditions: incubation at 50 ºC for 2 min and initial denaturation at 95 ºC for 10 min, then 50 
cycles of denaturation at 95 ºC for 15 s and annealing at 60 ºC for 1 min, and elongation for 
30 s at 72 ºC. Gain was set to 7 and fluorescence was acquired after elongation step. The PCR 
reaction mixtures (20 l) contained 9 l cDNA diluted 10-times in Milli-Q ultrapure water 
(Biocel A10, Millipore, Billerica, MA, USA), 10 l TaqMan Universal PCR Master Mix 
(Applied Biosystems, Foster City, CA, USA) and 1 l TaqMan Gene Expression Assay Mix 
(commercially available unlabeled PCR primers and FAMTM dye-labelled probe for rat 
CYP1A1/2 or NQO1 as target genes and β-actin as reference internal standard gene). Each 
sample was analysed in two parallel aliquots. Negative controls had the same compositions as 
samples but cDNA was omitted from the mixture. Data were analyzed by the program 
RotorGene v6 (Corbett Research, Sydney, Australia) and evaluated by comparative cycle 
threshold (cT) method for relative quantitation of gene expression. Cycle thresholds, at which 
a significant increase in fluorescence signal was detected, were measured for each sample. 
Then ΔΔcT was evaluated according to following equations: ΔcT = cT (target) - cT (internal 
standard), ΔΔcT = ΔcTtreated - ΔcTcontrol, where ΔcTtreated is ΔcT for treated rats and ΔcTcontrol is 
ΔcT for untreated rats. ΔcT is positive if the target is expressed at a lower level than the 
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internal standard (-actin), and negative if expressed at a higher level. The induction of 
mRNA expression of studied target genes in treated animals was evaluated as 2-(ΔΔcT). 
 
2.5. Preparation of antibodies and estimation of CYP1A1, 1A2, and NQO1 protein content in 
microsomal and cytosolic fractions isolated from rat liver and kidney 
The chicken anti-rat CYP1A1, anti-rabbit CYP1A2 and anti-rat NQO1 antibodies were 
prepared as described previously (Stiborová et al., 2002b, 2006). Immunoquantification of 
microsomal CYP1A1 and 1A2 and cytosolic NQO1 was performed using Western blotting 
(Stiborová et al., 2006). Rat CYP1A1, rat CYP1A2 and human NQO1 (Sigma) were used to 
identify the CYP1A1, 1A2 and NQO1 bands, respectively. The antigen-antibody complex 
was visualized with an alkaline phosphatase-conjugated rabbit anti-chicken IgG antibody and 
5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium as dye and bands are expressed 
as arbitrary units (AU)/mg protein (Stiborová et al., 2002b, 2006). Glyceraldehyde phosphate 
dehydrogenase was used as loading control and detected by its antibody (1:750, Millipore; 
MA, USA). 
 
2.6. NQO1, CYP1A1/2 and 2C6/11 enzyme activity assays 
In hepatic, renal and pulmonary cytosols NQO1 activity was measured using menadione 
(2-methyl-1,4-naphthoquinone) as a substrate; the assay was improved by the addition of 
cytochrome c and NQO1 activity expressed as nmol cytochrome c reduced  (Levová et al., 
2011, 2012). Microsomal samples were characterized for specific CYP1A1 and 1A2 
activities: Sudan I hydroxylation to 4’-hydroxy-, 6-hydroxy-, and 4’,6-dihydroxy-Sudan I 
(CYP1A1) (Stiborová et al., 1988, 2002b, 2005c) and methoxyresorufin O-demethylation 
(MROD) (CYP1A2) (Burke et al., 1994). Hepatic microsomal samples were also 
characterized for specific CYP2C6 and 2C11 activities with their marker substrates 
determining diclofenac 4’-hydroxylation and testosterone 16-hydroxylation, respectively 
(Kobayashi et al., 2002; Yamazaki et al., 2006).  
 
2.7. Microsomal incubations to study AAI demethylation 
Incubation mixtures contained 100 mM potassium phosphate buffer (pH 7.4), 1 mM 
NADPH, 1 mg rat hepatic, renal or pulmonary microsomal protein and 10 M AAI in a final 
volume of 250 l and were incubated at 37C for 20 min; AAI O-demethylation to AAIa was 
determined to be linear up to 25 min. Control incubations were carried out either (i) without 
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microsomes, (ii) without NADPH or (iii) without AAI. AAI and its metabolite AAIa were 
separated by reverse-phase HPLC, identified by mass spectrometry and quantified as 
described previously (Levová et al., 2011). Briefly, HPLC was carried out with an Nucleosil 
100-5 C18, 250  4.0 mm, 5 mm (Macherey-Nagel) column, using a linear gradient of 
acetonitrile (20 to 60% acetonitrile in 55 min) in 100 mM triethylamonium acetate with a 
flow rate of 0.6 ml/min. A Dionex HPLC pump P580 with UV/VIS UVD 170S/340S 
spectrophotometer detector set at 254 nm was used. Peaks were integrated with 
CHROMELEON™ 6.01 integrator. A peak eluting at retention time (r.t.) 22.7 min was 
identified as AAIa using mass-spectroscopy analysis (Levová et al., 2011). A typical HPLC 
chromatogram is shown in Supplementary Figure 1. 
 
2.8. Microsomal and cytosolic formation of AAI-DNA adducts 
The de-aerated and nitrogen-purged incubation mixtures, in which microsomes were used 
to activate AAI contained 50 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, 1 mg 
of hepatic or renal microsomal protein, 0.5 mg of calf thymus DNA (2 mM dNp) and 0.5 mM 
AAI in a final volume of 750 l. Microsomal incubations were carried out at 37C for 60 
min; AAI-DNA adduct formation was found to be linear up to 2 h in microsomes (Stiborová 
et al., 2005a). Control incubations were carried out either (i) without microsomes, (ii) without 
NADPH, (iii) without DNA or (iv) without AAI. After extraction with ethyl acetate, DNA 
was isolated from the residual water phase as described above (Stiborová et al., 2005a, 2011a, 
2012; Arlt et al., 2011).  
The  de-aerated and nitrogen-purged incubation mixtures, in which cytosols were used to 
activate AAI contained 50 mM Tris-HCl buffer (pH 7.4), 0.2% Tween 20, 1 mM NADPH, 1 
mg rat hepatic or renal cytosolic protein, 0.5 mg calf thymus DNA (2 mM dNp) and 0.5 mM 
AAI in a final volume of 750 l. Incubations with cytosols were performed at 37C for 60 
min; AAI-derived DNA adduct formation was found to be linear up to 2 h (Stiborová et al., 
2003). Control incubations were performed either (i) without cytosol, (ii) without NADPH, 
(iii) without DNA or (iv) without AAI. After extraction with ethyl acetate DNA was isolated 
from the residual water phase by the phenol/chloroform extraction method as described 
above. 
 
2.9. Statistical Analyses 
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For statistical data analysis we used Student’s t-test. All P-values are two-tailed and 
considered significant at the 0.05 level.  
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3. Results 
3.1. DNA adduct formation in rats treated with AAI and Sudan I compared to adduct 
formation in rats treated with AAI alone 
AAI-DNA adduct formation was determined by 32P-postlabeling in liver, kidney and 
lung of male Wistar rats treated i.p. with AAI, Sudan I, or AAI after pretreatment with Sudan 
I. Using the nuclease P1 version of 32P-postlabeling assay, all liver, kidney and lung samples 
from rats treated with AAI showed an adduct pattern similar to that found in kidney tissue 
from AAN and BEN patients (Arlt et al., 2002b; Nortier et al., 2000; Schmeiser et al., 1996, 
1997, 2012). As shown in Figure 2, the adduct pattern consisted of three adduct spots. These 
spots have been identified as 7-(deoxyguanosin-N2-yl)aristolactam I (dG-AAI), 7-
(deoxyadenosin-N6-yl)aristolactam I (dA-AAI) and 7-(deoxyadenosin-N6-yl)aristolactam II 
(dA-AAII). We have shown previously that the dA-AAII adduct can also be generated from 
AAI, probably via a demethoxylation reaction of AAI or dA-AAI (Stiborová et al., 1994; 
Schmeiser et al., 1997). No AAI-derived DNA adducts were found in DNA of control rats 
treated either with vehicle or Sudan I only (data not shown).  
Generally, AAI-DNA adduct levels were higher in liver, the organ predominantly 
responsible for biotransformation of xenobiotics including AAI, as well as kidney, the target 
organ of AAI genotoxicity (Stiborová et al., 2008a, b, 2014a, b), than in lung (Fig. 2). In all 
organs of rats treated with AAI after pretreatment with Sudan I, the levels of AAI-DNA 
adducts were only half of those in rats exposed to AAI alone (Fig. 2 and Supplementary Table 
1). Therefore, Sudan I, when administered to rats before their exposure to AAI, shifts the 
metabolic pathway of AAI that finally leads to a decrease in AAI-DNA adduct levels in all 
three organs. 
Because CYP1A1/2 enzymes both oxidize (i.e. detoxify AAI) and reduce (i.e. activate 
AAI to form to AAI-DNA adducts) AAI, their expression might determine the balance 
between activation and detoxification pathways of AAI (Stiborová et al., 2008a, b, 2013b, 
2014a, b). Therefore, we investigated whether expression levels of these enzymes influence 
AAI-DNA adduct formation found in vivo (Fig. 2 and Supplementary Table 1).  
 
3.2. The effect of AAI treatment with or without Sudan I upon CYP1A1/2 and NQO1 mRNA 
and protein levels and their enzymatic activities in rat liver, kidney and lung 
The effect of exposure to AAI, Sudan I and both compounds on expression of CYP1A1 
and 1A2 at the mRNA and protein levels, was examined in liver, kidney and lung.  
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The mRNA and protein of CYP1A1 (Table 1 and Fig. 3) were expressed in all organs of 
control rats. Sudan I oxidation, a marker for CYP1A1 enzyme activity (Stiborova et al., 
2002b, 2005c), was also detectable in all organs studied, but only very low Sudan I oxidation 
was measurable in kidney and lung, the organs expressing the lower protein levels of 
CYP1A1 than liver (Fig. 3). 
The CYP1A2 mRNA was expressed mainly in liver (Table 1), whereas the CYP1A2 
protein expression levels were higher in liver and lung than in kidney (Fig. 4). In 
concordance, MROD activity, a marker reaction of CYP1A2, was found in liver and lung, 
with no activity in kidney (see Fig. 4). 
As shown in Table 1, treatment of rats with Sudan I alone or with this compound before 
exposure to AAI induced expression of CYP1A1 mRNA in all tested organs. Treatment of rats 
with AAI alone induced mRNA levels of this CYP only in the liver and lung. The effect of 
both compounds combined was either the same as of Sudan I alone (lung and kidney) or led 
to lower mRNA levels in the liver. The most drastic effect was seen in the lung where Sudan I 
alone or in combination with AAI increased levels of CYP1A1 mRNA 2900-times as 
compared to AAI alone (Table 1). Expression of CYP1A1 protein and oxidation of Sudan I, a 
marker for CYP1A1, were always higher in organs of rats treated with AAI after pretreatment 
with Sudan I than with AAI alone (Fig. 3).  
Expression of mRNA and protein of CYP1A2 was also induced by treatment of rats with 
AAI, Sudan I or their combined administration (Table 1 and Fig. 4). In liver the mRNA, 
protein and CYP1A2 enzyme activities ran parallel, in kidney activities were detectable only 
in microsomes of rats treated with Sudan I or Sudan I combined with AAI. In lung the very 
high mRNA induction was not reflected in the phenotype; a decrease in amounts of CYP1A2 
protein found in lung of rats treated with AAI or Sudan I did not correspond to a 198- or 
6170-fold increase in the CYP1A2 mRNA expression levels (Fig. 4).  
The results found confirmed that Sudan I is a strong inducer of CYP1A1/2 in rats and 
indicate that a combined treatment of rats with Sudan I and AAI leads to even higher enzyme 
levels than with Sudan I alone. 
Treatment of rats with Sudan I and Sudan I combined with AAI also led to an increased 
expression of cytosolic NQO1, again at the mRNA, protein and enzyme activity levels in 
liver, kidney and lung (Table 1 and Fig. 5). Similarly to CYP1A, at the doses used, Sudan I 
resulted in greater increases at the protein level. Expression of mRNA, protein and enzyme 
activity of NQO1 measured with menadione as a substrate ran parallel in all three organs and 
were always higher in organs of rats treated with AAI and Sudan I than in those treated with 
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AAI alone (Fig. 5). However, the efficacy of NQO1 induction by AAI with Sudan I compared 
to AAI alone was lower than that for CYP1A expression (compare Figs. 3-5). These findings 
indicate that both compounds administered to rats act as moderate inducers of NQO1.  
 
3.3. The effect of treatment of rats with AAI, Sudan I and both agents in combination on 
oxidation of AAI to AAIa by rat hepatic, renal and pulmonary microsomes  
Since microsomal CYP1A1 and 1A2 detoxify AAI to its oxidative O-demethylated 
metabolite AAIa (Sistkova et al., 2008; Rosenquist et al., 2010; Arlt et al., 2011a; Levová et 
al., 2011; Stiborová et al., 2012, 2013b, 2014a, 2014b, 2015b), AAIa formation from AAI 
was investigated ex vivo in hepatic, renal and pulmonary microsomes of all treatment groups. 
AAIa was formed by liver microsomes from the AAI plus Sudan I group at moderately higher 
levels as compared to microsomes of rats treated with AAI alone. But in kidney only Sudan I 
treatment alone increased AAIa formation 1.6-fold (P < 0.01), AAI had no effect or even 
inhibited oxidation of AAI (Fig. 6). In lung the low activity of CYP1A enzymes detectable 
essentially only in microsomes of rats exposed to both Sudan I and AAI (see the CYP1A1/2 
activities determined with their marker substrates shown in Figs. 3 and 4) was confirmed also 
by formation of AAIa, as AAIa was only detectable at low levels in pulmonary microsomes 
of this group (Fig. 6). These results indicate that CYP1A1/2 enzymes catalyze AAI 
demethylation to AAIa in test rat organs, but this activity does not seem to be very effectively 
induced by Sudan I either alone or in combination with AAI. 
A probable reason for this observation is that not only CYP1A1/2, but also enzymes of 
the 2C subfamily, which are highly expressed in the livers of male rats, accounting for 
approximately 55% of the rat liver CYP complement (Nedelcheva et al., 1994), can oxidize 
AAI. CYP2C11 with 50% and CYP2C6 at 20% are the main members of the hepatic 
CYP2C family in rats (Večeřa et al., 2011; Zachařová et al., 2012). Both have been shown to 
be capable of efficiently oxidizing AAI to AAIa (Levová et al., 2011; Stiborová et al., 2014c, 
2015a, b), and the contribution of the CYP2C enzymes to AAIa formation in rat liver 
microsomes is more than 4-times higher than that of CYP1A (Stiborová et al., 2015b). Upon 
induction of CYP1A with Sudan I the relative amount of the CYP2C enzymes in the 
microsomes will decrease leading to lower CYP2C activity if analyzed based on mg protein, 
as was the case in our study. To test this, CYP2C activity was also analyzed in hepatic 
microsomes using diclofenac 4’-hydroxylation for CYP2C6 and testosterone 16-
hydroxylation as a marker for CYP2C11 (Kobayashi et al., 2002; Yamazaki et al., 2006). As 
shown in Figure 7 exposure of rats to Sudan I, either with or without AAI, decreased 
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testosterone 16-hydroxylation activities based on mg protein up to 33% relative to control 
while diclofenac 4’-hydroxylation was marginally lower. Therefore, decreased relative 
CYP2C activity could explain why AAIa formation in liver microsomes of rats treated with 
AAI, Sudan I or with a combination of both compounds did not run parallel to CYP1A 
induction tested with their marker activities, namely, Sudan I oxidation and MROD. 
 
3.4. Microsomal versus cytosolic activation of AAI 
In further experiments we investigated whether induction of microsomal CYP1A1/2 and 
cytosolic NQO1 also influences the reductive activation of AAI to AAI-DNA adducts 
catalyzed by rat microsomal and cytosolic fractions ex vivo. For the investigations we focused 
on the liver and kidney (target organ for AAI genotoxicity).  
AAI-DNA adduct formation was analyzed in ex-vivo incubations under hypoxic 
conditions. Incubation mixtures were purged with a stream of nitrogen for 2 minutes before 
the addition of AAI. AAI was reductively activated by both hepatic and renal microsomes 
from all treatment groups (Fig. 8). The adduct pattern generated was the same as that found in 
vivo (see Fig. 2). No adducts were observed in control incubations carried out in parallel (data 
not shown). A significant  two to three-fold increase in AAI-DNA adduct formation was seen 
in incubations of DNA with AAI and hepatic or renal microsomes of rats exposed to Sudan I 
alone or in combination with AAI (Fig. 8). Overall, the increases in AAI-DNA adduct 
formation ex vivo corresponded to the induction of CYP1A1/2 at protein levels in rats and 
confirmed the participation of these CYPs in the reductive activation of AAI found previously 
(Stiborová et al., 2001, 2005a, b, 2012, 2014b). The AAI-DNA adduct formation by 
microsomes under the oxidative (i.e. aerobic) conditions was not analyzed in this study. 
Namely, under these conditions the oxidation of AAI in microsomes (see Fig. 6) should 
compete with its reduction, which finally result in decreased levels of AAI-DNA adducts. 
Indeed, as shown in our previous study, an inhibition of AAI-DNA adduct formation occurred 
in the microsomal system under the aerobic conditions (Schmeiser et al., 1997).  
Cytosols, where NQO1 is expressed, were also incubated with AAI, calf thymus DNA 
and NADPH, the cofactor of NQO1, and analyzed for DNA adduct formation by 32P-
postlabeling. AAI was activated by hepatic cytosols as evidenced by specific AAI-DNA 
adduct formation (Fig. 8). No DNA adducts were observed in control incubations carried out 
in parallel (data not shown). Liver cytosols from rats treated with AAI, Sudan I and AAI after 
pretreatment with Sudan I produced AAI-DNA adduct levels which were 1.2-, 4.3- and 4.5-
fold higher, respectively, relative to cytosols isolated from untreated animals (Fig. 8). The 
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increase in AAI-DNA adduct formation ran parallel to higher NQO1 activity in these cytosols 
(compare Fig. 5). Renal cytosols isolated from AAI-treated rats, rats treated with Sudan I and 
rats treated with Sudan I plus AAI led to 1.1-, 3.9- and 4.2-fold higher AAI-DNA adduct 
levels relative to cytosols from control animals, respectively. Again, the observed adduct 
levels was consistent with the observed NQO1 enzyme activity (compare Figs. 5 and 8).   
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4. Discussion 
CYP1A1 and 1A2 have the dual function to catalyze AAI detoxification to AAIa and 
the activation of AAI to form AAI-DNA adducts. The aim of this study was to evaluate which 
of the two opposing functions prevails in an experimental rat model in vivo. Here we 
modulated the expression of CYP1A1/2 by Sudan I treatment which is a strong inducer of 
these enzymes (Stiborová et al., 2013a; Refat et al., 2008). As a measure of genotoxicity the 
formation of AAI-DNA adducts was determined. The formation of AAIa was used as a 
measure for AAI detoxification.  
The results of this study demonstrate that AAI-DNA adducts are formed in vivo in all 
organs tested (liver, kidney and lung), both in rats treated with AAI alone or in combination 
with the inducer Sudan I. These findings suggest that AAI is distributed via the blood stream 
and that these tissues have the metabolic capacity to reductively activate this carcinogen. The 
levels of AAI-DNA adducts in individual organs therefore depend both on a distribution of 
AAI to individual organs and on the activities of enzymes catalyzing either its oxidative 
detoxification or its reductive activation to species forming AAI-DNA adducts. Indeed, our 
results demonstrate that expression levels of CYP1A enzymes modulate the metabolism of 
AAI in the rat organs, thereby dictating AAI-DNA adduct formation in vivo. Furthermore, it 
is probable that enhanced clearance of AAI in the liver of induced animals is also altering the 
levels of AAI-DNA adducts in the kidney. 
In our study rats were exposed to AAI for 24 h only to resolve the role of CYP1A1/2 in 
AAI oxidative or reductive metabolism in vivo. We had previously shown  the formation of 
AAI-DNA adducts in liver and kidney 24 h after administration (Pfau et al., 1990; Stiborová 
et al., 1994, 2014c; Arlt et al., 2002b). Therefore, for these experimental purposes and to 
study the acute effects we used this short exposure, in order to resolve the role of CYP1A1/2 
in AAI oxidative or reductive metabolism in vivo. Our results indicate that under these 
conditions AAI genotoxicity (i.e. AAI-DNA adduct formation) is reduced after administration 
of the CYP1A1/2 inducer Sudan I. However, it is important to note that the doses to which 
humans are exposed to are orders of magnitude lower than the AAI dose administered to rats 
in this study and its effect at lower but chronic and life-long doses may be different. We 
found that only half of the AAI-DNA adduct levels were formed in liver, kidney and lung of 
rats treated with AAI after exposure to Sudan I, than in rats treated with AAI alone (see Fig. 
2). These findings demonstrate that induction of CYP1A1 and 1A2 by Sudan I might increase 
AAI detoxification, leading to lower amounts of AAI available for activation. However, only 
1.3-fold higher AAI detoxification (O-demethylation activity) was found ex vivo in 
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microsomes of treated rats. Previous studies have shown that CYP2C enzymes are also 
capable in O-demethylating AAI (i.e. AAI detoxification), and are even more efficient than 
the CYP1A enzymes to catalyze this reaction in rat liver microsomes (Stiborová et al., 2014c, 
2015b). CYP2C enzymes constitute about 55% of hepatic CYPs in male rats, Sudan I alone or 
in combination with AAI induces CYP1A about 4-fold, thereby reducing the relative amount 
of the other CYP enzymes. In microsomes from CYP1A induced rats, the contribution of 
CYP2C is therefore lower by a factor of approximately 4 explaining the relatively weak 
induction of AAIa formation we observed in such microsomes. 
The results of the present study fit with the proposed scheme of AAI metabolism (see 
Fig. 1). If AAI is oxidized to AAIa, lower amounts of AAI are available to be activated by 
enzymes with nitroreductase activity like NQO1 (for a review, see Stiborová et al., 2008b, c, 
2014a, b, c) which generate cyclic acylnitrenium ions that bind to DNA (i.e. DNA adduct 
formation) (Fig. 1). Our results are in accordance with two previous studies showing that AAI 
detoxification is lower in Cyp1a knockout mice (i.e. Cyp1a1(-/-), Cyp1a2(-/-) and Cyp1a1/2(-
/-) mouse lines) leading to an increase in AAI (geno)toxicity (Rosenquist et al., 2010; Arlt et 
al., 2011).  
Our results of the ex-vivo experiments also confirm previous findings (Stiborová et al., 
2001, 2012; Arlt et al., 2011; Levová et al., 2011) that under hypoxic (anaerobic) conditions, 
rat hepatic and renal CYP1A enzymes are capable of reducing AAI to species forming DNA 
adducts. Induction of CYP1A proteins and their enzyme activities correlated with increased 
AAI-DNA adduct formation ex vivo (Fig. 8). Therefore, induction of CYP1A1 and 1A2 leads 
to both oxidation and reduction of AAI which indicates that in case of hypoxia AAI must act 
as a ligand of CYP1A heme iron under low pO2. Indeed, reduction of AAI as a ligand of 
heme iron of CYP1A1 and 1A2 could be confirmed by molecular modeling (Jerabek et al., 
2011; Stiborová et al., 2014b). On the other hand, under aerobic conditions AAI acts as a 
classical substrate of CYP1A1 or 1A2, and takes one atom of atmospheric oxygen to O-
demethylate the methoxy group of AAI to generate AAIa. In line with this suggestion is the 
finding that binding of AAI to the active site of the Compounds I of CYP1A1 and 1A2 indeed 
favors O-demethylation of AAI to AAIa (see Fig. 5 in Stiborová et al., 2015b). However, as 
shown in Figure 2, the increased reductive activation of AAI ex vivo had no apparent impact 
on the reductive metabolism of AAI in vivo; AAI-DNA adduct formation was attenuated by 
induction of CYP1A enzymes. Likewise, induction of cytosolic NQO1, which led to an 
increase in AAI-DNA adduct formation ex vivo, had no significant effect in vivo, as a 
decrease in AAI-DNA adduct levels was observed. These findings demonstrate that in vivo 
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the oxygen concentrations in rat tissues are sufficient to facilitate the process of the oxidative 
O-demethylation of AAI, which is thereafter the predominant reaction of CYP1A1/2 in AAI 
metabolism in vivo. Therefore, in addition to the influence of CYP1A expression, the in vivo 
pO2 in tissues is an important factor that affects the balance between nitroreduction and O-
demethylation of AAI, thereby influencing its (geno)toxicity and carcinogenicity. Indeed, the 
presence of oxygen in the in-vitro incubations of AAI with DNA and microsomal or cytosolic 
enzymes strongly inhibits the levels of AAI-DNA adducts formed in these systems 
(Schmeiser et al., 1997).  
Based on the present study and taking into account previous results obtained in Cyp1a-
knock-out and CYP1A-humanized mouse lines (Rosenquist et al., 2010; Arlt et al., 2011; 
Stiborová et al., 2012; 2014a; b; c), we conclude that the efficiency of the CYP1A family to 
protectively oxidize AAI to AAIa prevails over its reducing activation in vivo. The evaluation 
of inter-individual variations in the human CYP1A enzymes, including their genetic 
polymorphisms, remains a major challenge to explain human individual susceptibility to AAI, 
and to predict the risk of cancer among patients suffering from AAN and BEN. 
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Table 1  
Relative expression of mRNA of hepatic, renal and pulmonary CYP1A1, CYP1A2 and 
NQO1 in liver, kidney and lung from untreated (control) animals and animals treated with 
AAI, Sudan I or AAI combined with Sudan I.  
 
 Liver Kidney Lung 
  cT 1 
Fold Change  
over Control 
cT 1 
Fold Change  
over Control 
cT 1 
Fold Change  
over Control 
C
Y
P
1
A
1
 
control 12.84 ± 0.44 1.00 7.22 ± 0.22 1.00 15.20 ± 0.15  1.00 
AAI 9.93 ± 0.44 7.54*** 7.56 ± 0.27 0.791 13.53 ± 0.29 3.19** 
Sudan I 0.36 ± 0.06 5710*** 4.53 ± 0.35 6.45*** 2.08 ± 0.04 8930*** 
Sudan I + AAI 1.56 ± 0.31 2490*** 4.53 ± 0.17 6.63*** 2.05 ± 0.22 9090*** 
C
Y
P
1
A
2
 
control 0.75 ± 0.34 1.00 16.38 ± 0.42 1.00 19.89 ± 0.18 1.00 
AAI -2.22 ± 0.08 7.86*** 14.60 ± 0.32  3.43** 12.26 ± 0.26 198*** 
Sudan I -5.23 ± 0.44 63.2*** 7.85 ± 0.25 370*** 7.30 ± 0.26 6170*** 
Sudan I + AAI -5.76 ± 0.16 91.5*** 8.72 ± 0.82 202*** 10.67 ± 0.43 595*** 
N
Q
O
1
 
control 6.03 ± 0.24 1.00 7.51 ± 0.16 1.00 5.98 ± 0.46 1.00 
AAI 2.10 ± 0.29 15.2*** 7.27 ± 0.18 1.18 5.66 ± 0.27 1.25 
Sudan I 1.06 ± 0.22 31.2*** 5.88 ± 0.28 3.10** 2.97 ± 0.08 8.06*** 
Sudan I + AAI 1.47 ± 0.28 23.5*** 6.05 ± 0.31 2.76** 3.42 ± 0.44 5.92*** 
 
 
1 Values relative to β-actin are means ± S.D. from data found for three male rats (n = 3) 
(control and treated with AAI, Sudan I and AAI with Sudan I). The induction of mRNA 
expression of studied target genes in treated animals was evaluated as 2-(ΔΔcT) (see Material 
and Methods). Comparison was performed by Student’s t-test analysis; **P > 0.01; ***P > 
0.001 significantly different from controls. 
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Legends to Figures 
 
Fig. 1. Activation and detoxification pathways of AAI. dA-AAI, 7-(deoxyadenosin-N6-
yl)aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; CYP1A1/2, 
cytochrome P450 1A1 and 1A2; CYP2C9, cytochrome P450 2C9;  CYP3A4, cytochrome 
P450 3A4;   NQO1, NAD(P)H:quinone oxidoreductase. 
Fig. 2. Quantitative TLC 32P-postlabeling analysis of AAI-DNA adduct levels in organs of 
rats treated with AAI, Sudan I or AAI after exposure to Sudan I. Numbers above columns 
(“F”) indicate fold changes in DNA adduct levels in animals treated with AAI combined 
with Sudan I compared to animals treated with AAI alone. Values are given as the means 
 SD (n = 3); each DNA sample was determined by two postlabeled analyses. RAL, 
relative adduct labeling. Comparison was performed by t-test analysis; ***P < 0.001, 
different from animals treated with AAI alone. Insert: Autoradiographic profile of AAI-
DNA adducts formed in liver of rats treated with AAI, determined by the nuclease P1 
enrichment version of the 32P-postlabeling assay. 
Fig. 3. CYP1A1 protein levels (upper panels) in rat microsomes isolated from untreated 
(control) animals and animals treated with AAI, Sudan I or AAI after exposure to Sudan I. 
Microsomes isolated from liver, kidney and lung were analyzed by Western blotting in 
the same blot (insert) and, therefore, can be compared directly. Values are given as the 
means of arbitrary units (AU per mg protein)  SD (n = 3). CYP1A1 enzyme activity as 
measured by Sudan I oxidation (nmol total C-hydroxylated Sudan I metabolites/min x mg 
protein) (lower panels). All values are given as the means  SD (n = 3). Numbers above 
columns (“F”) indicate fold changes in protein level or enzyme activity in microsomes of 
rats treated with AAI with Sudan I compared to those with AAI alone. Comparison was 
performed by t-test analysis; **P < 0.01, ***P < 0.001, different from data found in 
microsomes form rats treated with AAI alone. 
Fig. 4.  CYP1A2 protein levels (upper panels) in rat microsomes isolated from untreated 
(control) animals and animals treated with AAI, Sudan I or AAI after exposure to Sudan I. 
Microsomes isolated from liver, kidney and lung were analyzed by Western blotting in 
the same blot (insert) and, therefore, can be compared directly. Values are given as the 
means of arbitrary units (AU per mg protein)  SD (n = 3). CYP1A2 enzyme activity as 
measured by MROD (pmol resorufin/min x mg protein) (lower panels). All values are 
given as the means  SD (n = 3). Numbers above columns (“F”) indicate fold changes in 
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protein level or enzyme activity in microsomes of rats treated with AAI with Sudan I 
compared to those with AAI alone. Comparison was performed by t-test analysis; *P < 
0.05, ***P < 0.001, different from data found in microsomes form rats treated with AAI 
alone. 
Fig. 5. NQO1 protein levels (upper panels) and NQO1 enzyme activity (lower panels) in rat 
cytosols isolated from untreated (control) animals and animals treated with AAI, Sudan I 
or AAI after pretreatment with Sudan I. Cytosol isolated from liver, kidney or lung was 
analyzed by Western blotting in the same blot (insert) and, therefore, can be compared 
directly. Human recombinant NQO1 was used to identify the rat NQO1 band in rat 
cytosol (data not shown). Values are given as the means of arbitrary units (AU per mg 
protein)  SD (n = 3). NQO1 activity in hepatic, renal and pulmonary cytosols was 
determined using menadione and cytochrome c as substrate (expressed as nmol 
cytochrome c reduced/min x mg protein). Numbers above columns (“F”) indicate fold 
changes in protein level or enzyme activity in cytosols of rats treated with AAI with 
Sudan I compared to those with AAI alone. Values are given as the means  SD (n = 3). 
Comparison was performed by t-test analysis; **P < 0.01, ***P < 0.001, different from 
data found in cytosols of rats treated with AAI alone. 
Fig. 6. Formation of AAIa (peak area per minute per miligram protein) in rat microsomes 
isolated from untreated (control) animals and animals treated with AAI, Sudan I or AAI 
after exposure to Sudan I with AAI as a substrate. All values are given as the means  SD 
(n = 3). Numbers above columns (“F”) indicate fold changes in AAIa levels in 
microsomes of rats treated with AAI with Sudan I compared to those with AAI alone. 
ND, not detected. Comparison was performed by t-test analysis; ***P < 0.001, different 
from data found in microsomes of rats treated with AAI alone. 
Fig. 7. CYP2C6 (A) and CYP2C11 enzyme activities (B) in rat hepatic microsomes. CYP2C6 
was measured as diclofenac 4’-hydroxylation (nmol 4’-hydroxydiclofenac/min x mg 
protein) and CYP2C11 as testosterone 16-hydroxylation (nmol 16-
hydroxytestosterone/min x mg protein). All values are given as the means  SD (n = 3). 
Numbers above columns (“F”) indicate fold changes in enzyme activities compared to 
control. Comparison was performed by t-test analysis; ***P < 0.001, different from 
control. 
Fig. 8. DNA adduct formation ex vivo by AAI in rat microsomes (upper panels) and cytosols 
(lower panels) isolated from liver and kidney of untreated (control) animals and animals 
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treated with AAI, Sudan I or AAI after exposure to Sudan I and incubated with DNA, 
AAI and NADPH. AAI-DNA adduct formation was determined by 32P-postlabeling. 
Values are given as the means  SD (n = 3); each DNA sample was determined by two 
postlabeling analyses. RAL, relative adduct labeling. Numbers above columns (“F”) 
indicate fold changes in AAI-DNA adduct levels in microsomes and cytosols of rats 
treated with AAI with Sudan I compared to those with AAI alone. Comparison was 
performed by t-test analysis; ***P < 0.001, different from data found with microsomes or 
cytosols of rats treated with AAI alone. 
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Figure 5 
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